Thank You to Our 2014 Summit Supporters
Demonstrating the collaborative nature of the Knowledge Network Summit, we are pleased to announce this year’s supporters: Netsmart, Qol Meds, Genoa, SBR Health and myStrength.
What our supporters have to say about the Summit:
“We speak at and sponsor this summit because of the state-of-the-art dialogue on key issues that drive clinical quality, tracking the impact and measuring the value of care. A major goal of Netsmart’s clinical strategy is innovating to contribute to the goal of zero suicides – this network helps to facilitate that goal,” said Kevin Scalia, executive vice president, Netsmart.
“Genoa Healthcare, the nation’s leading provider of specialty pharmacy services in behavioral healthcare, is pleased to support CRI’s Knowledge Network meeting. For many years Genoa has enjoyed a great partnership with CRI and we look forward to continuing this relationship to help better the lives of those living with mental illness.” – Mark Peterson, Executive Vice President, Genoa Healthcare
CRI Hosts its 10th Knowledge Network Summit
Centerstone Research Institute’s vision is to create a future where all individuals and families facing behavioral health disorders receive exceptional care grounded in mental and physical whole-person wellness. With analytics leading the conversation about technology in so many industries, we must ask ourselves, ‘How do we know when someone has received the exceptional care we envision?’
The power of prescriptive analytics finally enables us to ask, “For each individual coming in, what would be the optimal course of treatment for them?” And, right now, the entire spectrum of healthcare providers must also ask themselves, “How will providers measure success?” read more
Knowledge Network Summit Agenda & Registration
Thomas W. Mahler Jr. Named Chair of CRI’s Board of Directors
Centerstone Research Institute (CRI), a not-for-profit organization dedicated to improving behavioral healthcare through research and information technology, today announced that Thomas W. Mahler Jr. has been named Chair of its Board of Directors. A member of CRI’s board since 2008, Mahler began his two-year term as Chair on January 29, 2014. read more
CRI Helps Individuals with Serious Mental Illness Quit Smoking
David Ayer, PhD, director of clinical research, and other investigators with Massachusetts General Hospital and Harvard Medical School in Boston, conducted a randomized clinical trial that showed the antismoking drug varenicline (Chantix, Pfizer Inc) boosts quit rates in smokers with serious mental illness. The trial was conducted at 10 community mental health centers, including a Centerstone site in Indiana, in the United States. The study was led by Anne Eden Evins, MD, MPH, of Massachusetts General Hospital, and published in the January 8 issue of JAMA.
Clinical Research Update
In fiscal year 2013, CRI’s clinical research office facilitated 19 ongoing and 11 new studies that involved 4,473 study participants. Research projects conducted at Centerstone clinics/sites involved 27 investigators located at 18 institutions including Indiana, Vanderbilt, Harvard, and Northwestern universities.